GGrantIndex
← Search

Molecular Cytogenetics

$162,279P30FY2010CANIH

University Of Tx Md Anderson Can Ctr, Houston TX

Investigators

Linked publications, trials & patents

Trial NCT07407920Trial NCT07349641Trial NCT06651580Trial NCT05681026Trial NCT05223036Trial NCT05078866Trial NCT05057312Trial NCT05054296Trial NCT05044546Trial NCT05023967Trial NCT05011045Trial NCT04875728Trial NCT04870645Trial NCT04810091Trial NCT04751422Trial NCT04740164Trial NCT04668300Trial NCT04615013Trial NCT04505267Trial NCT04484909Trial NCT04483349Trial NCT04481204Trial NCT04474301Trial NCT04458610Trial NCT04447222Trial NCT04435691Trial NCT04430725Trial NCT04407247Trial NCT04373720Trial NCT04317781Trial NCT04311723Trial NCT04310826Trial NCT04310397Trial NCT04265430Trial NCT04257045Trial NCT04256941Trial NCT04239989Trial NCT04239976Trial NCT04239157Trial NCT04236882Trial NCT04228042Trial NCT04220827Trial NCT04220775Trial NCT04220008Trial NCT04219969Trial NCT04219904Trial NCT04216732Trial NCT04216563Trial NCT04216524Trial NCT04216472Trial NCT04215029Trial NCT04200534Trial NCT04199026Trial NCT04196972Trial NCT04189783Trial NCT04189770Trial NCT04189757Trial NCT04188418Trial NCT04188405Trial NCT04186884Trial NCT04186832Trial NCT04185337Trial NCT04181463Trial NCT04171622Trial NCT04171219Trial NCT04171037Trial NCT04169763Trial NCT04169737Trial NCT04169542Trial NCT04160052Trial NCT04151082Trial NCT04150939Trial NCT04140487Trial NCT04135326Trial NCT04134208Trial NCT04132843Trial NCT04132505Trial NCT04132440Trial NCT04129138Trial NCT04128748Trial NCT04128501Trial NCT04127721Trial NCT04125914Trial NCT04119037Trial NCT04106843Trial NCT04106245Trial NCT04090619Trial NCT04090567Trial NCT04087057Trial NCT04083378Trial NCT04082572Trial NCT04074746Trial NCT04066894Trial NCT04062305Trial NCT04062266Trial NCT04058964Trial NCT04054245Trial NCT04054167Trial NCT04054154Trial NCT04053517

Abstract

The Molecular Cytogenetics Facility (MCF) provides basic and clinical investigators with conventional and FISH-based cytogenetic services. The goals of the core are to provide 1) high-quality, reasonably-priced cytogenetic services and expertise for requesting investigators;2) standard chromosome karyotyping and G, C, Q, R, silver staining to ascertain chromosomal abnormalities for evidence of genomic instability; 3) fluorescence in situ hybridization (FISH) of metaphase spreads using commercially- available chromosome paint probes, locus-specific probes, and telomere probes;4) Spectral Karyotyping (SKY) service to unambiguously identify, in one hybridization reaction, mouse or human chromosomal translocations present within a metaphase spread;5) specialized services, such as telomere length determination by Quantitative-FISH (Q-FISH), on an as-needed basis;and 6) access to personnel who are highly-experienced in a variety of cytogenetic technologies as well as access to the methodologies themselves. The MCF avoids expensive duplication in individual faculty laboratories of personnel, facilities, and equipment required for application of these powerful tools. The Facility occupies 250 sq. ft. within the Department of Cancer Genetics. An additional 200 sq. ft. microscope room houses 4 fluorescent microscopes for chromosomal analyses. The MCF is staffed with a Director, a Co-Director, 1 Laboratory Assistant, 'and a Professor Emeritus. During the previous funding period, 741 specimens were collected for both conventional and FISH-based cytogenetic services. Peer-funded investigators are given priority for MCF services that were used by 76 investigators from 18 of the 19 CCSG programs. 92% of users had peerreviewed funding and accounted for 85% of utilization. Since its inception, the MCF has successfully supported 5 peer-reviewed NIH-funded grants and investigators using data generated by the MCF have published extensively in top-tier journals. Future plans are to establish new cytogenetic services as well as to upgrade existing technologies.

View original record on NIH RePORTER →